Sujet(s)
Consensus , Facteurs immunologiques , Infections à papillomavirus , Dysplasie du col utérin , Tumeurs du col de l'utérus , Humains , Femelle , Dysplasie du col utérin/virologie , Tumeurs du col de l'utérus/virologie , Chine , Facteurs immunologiques/administration et posologie , Facteurs immunologiques/usage thérapeutique , Administration par voie topique , PapillomaviridaeRÉSUMÉ
Ovarian cancer is the most common malignant tumors of the female reproductive system, and its standard treatments are cytoreductive surgery and platinum-based adjuvant chemotherapy. Great advances have been achieved in novel treatment strategies, including targeted therapy and immunotherapy. However, ovarian cancer has the highest mortality rate among gynecological tumors due to therapeutic resistance and the gap between preclinical data and actual clinical efficacy. Organoids are a 3D culture model that markedly affects gene analysis, drug screening, and drug sensitivity determination of tumors, especially when used in targeted therapy and immunotherapy. In addition, organoid can lead to advances in the preclinical research of ovarian cancer due to its convenient cultivation, good genetic stability, and high homology with primary tumors.
